Atacicept: targeting B cells in multiple sclerosis
Open Access
- 9 June 2010
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 3 (4) , 205-216
Abstract
Multiple sclerosis (MS) has traditionally been considered to be a T-cell-mediated disease. However, there is an increasing body of evidence for the involvement of B cells and autoantibodies in the pathology of this disease, providing a rationale for treatments directed against B cells. In this paper we summarize evidence for the key role of B cells in the immunopathology of MS and review data supporting the use of a novel B-cell targeted therapy, atacicept, in this condition. Atacicept is a human recombinant fusion protein that comprises the binding portion of a receptor for both BLyS (B-Lymphocyte Stimulator) and APRIL (A PRoliferation-Inducing Ligand), two cytokines that have been identified as important regulators of B-cell maturation, function and survival. Atacicept has shown selective effects on cells of the B-cell lineage, acting on mature B cells and blocking plasma cells and late stages of B-cell development while sparing B-cell progenitors and memory cells. The efficacy of atacicept in animal models of autoimmune disease and the biological activity of atacicept in patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been demonstrated. Clinical studies were initiated to investigate the safety, tolerability and efficacy of atacicept in patients with MS. An unexpected increase in inflammatory activity in one of the trials, however, led to suspension of all atacicept trials in MS.Keywords
This publication has 91 references indexed in Scilit:
- Mechanism of Action of Oral Fingolimod (FTY720) in Multiple SclerosisClinical Neuropharmacology, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemBritish Journal of Pharmacology, 2009
- Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid ArthritisThe Journal of Clinical Pharmacology, 2008
- Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MSJournal of Neuroimmunology, 2007
- The Immunopathology of Multiple Sclerosis: An OverviewBrain Pathology, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Immunopathologic role of B lymphocytes in rheumatoid arthritis: Rationale of B cell-directed therapyAutoimmunity Reviews, 2006
- Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation?Journal of Experimental Medicine, 1999